Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;70(6):1885-1888.
doi: 10.1002/hep.30946.

The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH

Rohit Loomba  1   2 , Leon A Adams  3   4
Affiliations
Editorial

The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH

Rohit Loomba et al. Hepatology. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: LA holds patents for Hepascore.

Figures

FIG. 1.
FIG. 1.
The natural history of disease progression in NASH with advanced fibrosis and cirrhosis: the 20% rule. Approximately 20% of patients with NASH with advanced NAFLD Fibrosis Score (NFS) (F3) fibrosis or compensated cirrhosis will progress to cirrhosis or develop decompensation, respectively, over a 2-year time period.
See this image and copyright information in PMC

Comment on

References

    1. Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol 2018;113:1649–1659. - PMC - PubMed
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84. - PubMed
    1. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.e310. - PMC - PubMed
    1. Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek M, Diehl AM, Caldwell S, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 2019;70:1913–1927. - PubMed
    1. Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, et al.; GS-US-321–0105 and GS-US-321–0106. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 2018;155:1140–1153. - PubMed

Publication types

Substances